Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV-2/4.hRPE65 Gene Therapy for Leber Congenital Amaurosis
NCT01496040Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Sep 2011
- Primary completion
- Aug 2014
- Countries
- 1
01
Overview
A Phase 2 trial of rAAV2/4.hRPE65 in Leber congenital amaurosis (LCA), sponsored by CHU de Nantes. Started Sep 2011; status: completed.
02
Drugs
rAAV2/4.hRPE65
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT01496040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496040.